Tricida (TCDAQ) and The Competition Critical Analysis
Tricida (TCDAQ) and The Competition Critical Analysis
Tricida (NASDAQ:TCDAQ – Get Rating) is one of 986 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it compare to its peers? We will compare Tricida to related companies based on the strength of its risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Tricida（納斯達克股票代碼：TCDAQ — Get Rating）是 “藥物製劑” 行業986家上市公司之一，但與同行相比如何？我們將根據Tricida的風險、盈利能力、收益、分析師建議、機構所有權、股息和估值的實力，將其與相關公司進行比較。
Risk & Volatility
風險與波動性
Tricida has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Tricida's peers have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Tricida的beta值爲0.07，這表明其股價的波動性比標準普爾500指數低93％。相比之下，Tricida的同行的beta值爲0.94，這表明他們的平均股價波動性比標準普爾500指數低6％。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and price targets for Tricida and its peers, as provided by MarketBeat.com.
這是Marketbeat.com提供的Tricida及其同行最近的評級和目標價格的明細。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tricida | 0 | 0 | 0 | 0 | N/A |
| Tricida Competitors | 4168 | 15026 | 41510 | 711 | 2.63 |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| Tricida | 0 | 0 | 0 | 0 | 不適用 |
| Tricida 競爭對手 | 4168 | 15026 | 41510 | 711 | 2.63 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 120.94%. Given Tricida's peers higher possible upside, analysts clearly believe Tricida has less favorable growth aspects than its peers.
作爲一個整體，“藥物製劑” 公司的潛在上漲空間爲120.94％。鑑於Tricida的同行可能更高的上行空間，分析師顯然認爲Tricida的增長方面不如同行那麼有利。
Earnings & Valuation
收益與估值
This table compares Tricida and its peers top-line revenue, earnings per share and valuation.
該表比較了Tricida及其同行的最高收入、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Tricida | N/A | -$176.57 million | 0.00 |
| Tricida Competitors | $1.82 billion | $242.10 million | -3.55 |
| 總收入 | 淨收入 | 市盈率 | |
| Tricida | 不適用 | -1.7657 億美元 | 0.00 |
| Tricida 競爭對手 | 18.2 億美元 | 2.421 億美元 | -3.55 |
Tricida's peers have higher revenue and earnings than Tricida. Tricida is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Tricida的同行比Tricida的收入和收益更高。Tricida的市盈率高於同行，這表明它目前比該行業的其他公司更昂貴。
Insider and Institutional Ownership
內部所有權和機構所有權
40.6% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 35.6% of Tricida shares are owned by insiders. Comparatively, 15.6% of shares of all "Pharmaceutical preparations" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
所有 “藥物製劑” 公司的40.6％的股份由機構投資者持有。35.6％的Tricida股份由內部人士持有。相比之下，所有 “藥物製劑” 公司的15.6％的股份由內部人士持有。強大的機構所有權表明，對沖基金、大型基金經理和捐贈基金認爲一家公司已爲長期增長做好了準備。
Profitability
盈利能力
This table compares Tricida and its peers' net margins, return on equity and return on assets.
該表比較了Tricida及其同行的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Tricida | N/A | N/A | -103.81% |
| Tricida Competitors | -3,495.77% | -222.94% | -34.54% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| Tricida | 不適用 | 不適用 | -103.81% |
| Tricida 競爭對手 | -3,495.77% | -222.94% | -34.54% |
Summary
摘要
Tricida peers beat Tricida on 6 of the 10 factors compared.
在比較的10個因素中，Tricida同行在6個因素上擊敗了Tricida。
About Tricida
關於 Tricida
(Get Rating)
（獲取評級）
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.
Tricida, Inc. 是一家制藥公司。它專注於其產品 TRC101 的開發和商業化，這是一種非吸收、口服給藥的聚合物藥物，旨在治療慢性腎臟病患者的代謝性酸中毒。該公司由格里特·克拉爾納和克雷格·喬恩·霍克於2013年5月22日創立，總部位於加利福尼亞州南舊金山。
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Tricida Daily 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Tricida及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。